4XC1

Kalvista Pharmaceuticals INC

+$370.2M

Net Activity

Institutions Holding

185

Popularity Rank

#3093

Avg Weight

0.39%

Total Value

$1.5B

Ownership Trend

185 institutions currently hold 4XC1, with 99 net buyers and 61 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

61

Net Buying Institutions

99

Key Holders

View all 185 holding institutions

Quarterly Activity

Recent Activity

+$599.9M

Total Buy Value

$512.2M

Total Sell Value

New buy33
Trim46
Add66
Sold out15

99

Net Buyers

61

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding KALVISTA PHARMACEUTICALS INC (4XC1)?
Major stakeholders currently include Venrock Adviser, LLC ($130.3M), Frazier Life Sciences Management, L.P. ($99.9M), Suvretta Capital Management, LLC ($96.0M). Based on the latest 13F filings, there are a total of 185 tracked investment funds and institutions maintaining positions in 4XC1.
What is the overall institutional sentiment toward 4XC1 recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $370.2M, driven by 99 managers accumulating shares while 61 reduced their exposure.
Which institutions have been selling or reducing their 4XC1 positions?
In the latest period, 46 funds trimmed their holdings, and 15 managers completely exited their positions. The aggregate reported sell value was $512.2M.
Are there any notable investors adding 4XC1 to their portfolios?
Yes, buying activity remains notable. 33 institutions opened new positions in {ticker}, and 66 existing holders added to their shares. The total reported buy value for the quarter amounted to $599.9M.

Related Stocks